Abstract

Regulatory Guidance for Conducting Clinical Trials in India

Author: Ms Ranjini D M, Dr G S Shantha Kumar

Doi: 10.62655/s-epub.2021.v13.i02.pp1-11

Abstract:

To protect the subjects from the promotion of dangerous drugs, the Central Drugs Standard Control Organisation and its administrator, the Drug Controller General of India (DCGI), are to go. It has come to light in the 59th report of the Parliamentary Standing Committee on Health and Family Welfare that the administrative experts in India adhere to loose and not properly managed regulations. There is a plethora of questionable prescriptions available, including unapproved and inappropriate FDCs that are irrelevant to the therapeutic requirements of India and are not offered in any country with sophisticated regulatory organisations. Since several Indian government ministries and departments are responsible for the administrative aspects of pharmaceuticals, it is crucial to understand their origins, evolution, and current in India, and inspecting clinical preliminary destinations. Regardless, the exploitative advances made by certain pharmaceutical organisations and therapeutic professionals, along with the laid-back approach to marketing and endorsement of medications, have highlighted the need to gain a proper understanding of the current direction of medications and clinical research, especially in regard to commonsense standards and controls.